Bio-Rad Laboratories, Inc. (BIO) Revenue CAGR:1.92%(TTM)
The revenue cagr for Bio-Rad Laboratories, Inc. (BIO) is +1.92% over the latest trailing 12-month period. Revenue CAGR uses precomputed financial statement history.
The revenue CAGR for Bio-Rad Laboratories, Inc. (BIO) stock is 1.92% over the past 12 months. The 3 year CAGR is -2.32% and the 5 year CAGR is -0.84%. Revenue CAGR measures how Bio-Rad Laboratories, Inc.'s top-line revenue has grown over time. Consistent revenue growth is a key indicator of business expansion and market share gains.
BIO Revenue CAGR Chart
Bio-Rad Laboratories, Inc. (BIO)
BIO Quarterly Revenue Growth (YoY)
Revenue growth vs the same quarter one year earlier, last 20 quarters.
BIO Revenue CAGR History
| Year | Start Revenue | End Revenue | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $2.57B | $2.58B | +$16.70M | +0.65% | +0.65% |
| 2024 | $2.67B | $2.57B | $-104.76M | -3.92% | -3.92% |
| 2023 | $2.80B | $2.67B | $-130.99M | -4.67% | -4.67% |
| 2022 | $2.92B | $2.80B | $-120.30M | -4.12% | -4.12% |
| 2021 | $2.55B | $2.92B | +$376.92M | +14.81% | +14.81% |
| 2020 | $2.31B | $2.55B | +$233.97M | +10.12% | +10.12% |
| 2019 | $2.29B | $2.31B | +$21.55M | +0.94% | +0.94% |
| 2018 | $2.16B | $2.29B | +$129.96M | +6.02% | +6.02% |
| 2017 | $2.07B | $2.16B | +$91.98M | +4.45% | +4.45% |
| 2016 | $2.02B | $2.07B | +$48.73M | +2.41% | +2.41% |
| 2015 | $2.18B | $2.02B | $-155.60M | -7.15% | -7.15% |
| 2014 | $2.13B | $2.18B | +$42.35M | +1.99% | +1.99% |
| 2013 | $2.07B | $2.13B | +$63.46M | +3.07% | +3.07% |
| 2012 | $2.07B | $2.07B | $-4.29M | -0.21% | -0.21% |
| 2011 | $1.93B | $2.07B | +$146.41M | +7.60% | +7.60% |
| 2010 | $1.78B | $1.93B | +$142.87M | +8.01% | +8.01% |
| 2009 | $1.76B | $1.78B | +$19.88M | +1.13% | +1.13% |
| 2008 | $1.46B | $1.76B | +$303.31M | +20.76% | +20.76% |
| 2007 | $1.27B | $1.46B | +$187.12M | +14.69% | +14.69% |
| 2006 | $1.18B | $1.27B | +$92.94M | +7.87% | +7.87% |
| 2005 | $1.09B | $1.18B | +$90.97M | +8.35% | +8.35% |
| 2004 | $1.00B | $1.09B | +$86.63M | +8.63% | +8.63% |
| 2003 | $892.72M | $1.00B | +$110.66M | +12.40% | +12.40% |
| 2002 | $817.51M | $892.72M | +$75.21M | +9.20% | +9.20% |
| 2001 | $725.88M | $817.51M | +$91.63M | +12.62% | +12.62% |
| 2000 | $549.50M | $725.88M | +$176.38M | +32.10% | +32.10% |
| 1999 | $441.90M | $549.50M | +$107.60M | +24.35% | +24.35% |
| 1998 | $426.90M | $441.90M | +$15.00M | +3.51% | +3.51% |
| 1997 | $418.80M | $426.90M | +$8.10M | +1.93% | +1.93% |
Quarterly Revenue: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $592.10M | -14.6% | +1.1% |
| Q4 2025 | $693.20M | +6.2% | +3.9% |
| Q3 2025 | $653.00M | +0.2% | +0.5% |
| Q2 2025 | $651.60M | +11.3% | +2.1% |
| Q1 2025 | $585.40M | -12.3% | -4.2% |
| Q4 2024 | $667.48M | +2.7% | -2.0% |
| Q3 2024 | $649.73M | +1.8% | +2.8% |
| Q2 2024 | $638.48M | +4.5% | -6.3% |
| Q1 2024 | $610.82M | -10.3% | -9.8% |
| Q4 2023 | $681.18M | +7.8% | -6.7% |
| Q3 2023 | $632.12M | -7.2% | -7.1% |
| Q2 2023 | $681.11M | +0.6% | -1.4% |
| Q1 2023 | $676.84M | -7.3% | -3.3% |
| Q4 2022 | $730.29M | +7.3% | -0.3% |
| Q3 2022 | $680.80M | -1.5% | -8.9% |
| Q2 2022 | $691.10M | -1.3% | -3.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz